BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 22578732)

  • 21. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.
    Walz J; Chun FK; Klein EA; Reuther A; Saad F; Graefen M; Huland H; Karakiewicz PI
    J Urol; 2009 Feb; 181(2):601-7; discussion 607-8. PubMed ID: 19084864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Partin AW
    J Urol; 2006 Oct; 176(4 Pt 1):1404-8. PubMed ID: 16952644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hazard of prostate cancer specific mortality after radical prostatectomy.
    Shikanov S; Eggener SE
    J Urol; 2012 Jan; 187(1):124-7. PubMed ID: 22114813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer.
    Liu L; Coker AL; Du XL; Cormier JN; Ford CE; Fang S
    J Surg Oncol; 2008 Jun; 97(7):583-91. PubMed ID: 18381603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy.
    Ciezki JP; Klein EA; Angermeier K; Ulchaker J; Chehade N; Altman A; Mahadevan A; Reddy CA
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1347-50. PubMed ID: 15590163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of age at diagnosis on prostate cancer mortality: a grade-for-grade and stage-for-stage analysis.
    Gandaglia G; Karakiewicz PI; Abdollah F; Becker A; Roghmann F; Sammon JD; Kim SP; Perrotte P; Briganti A; Montorsi F; Trinh QD; Sun M
    Eur J Surg Oncol; 2014 Dec; 40(12):1706-15. PubMed ID: 24915856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006.
    Abdollah F; Sun M; Thuret R; Jeldres C; Tian Z; Briganti A; Shariat SF; Perrotte P; Rigatti P; Montorsi F; Karakiewicz PI
    Eur Urol; 2011 Jan; 59(1):88-95. PubMed ID: 20965646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Competing mortality contributes to excess mortality in patients with poor-risk lymph node-positive prostate cancer treated with radical prostatectomy.
    Froehner M; Scholz A; Koch R; Hakenberg OW; Baretton GB; Wirth MP
    Urol Int; 2012; 89(2):148-54. PubMed ID: 22813937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
    Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
    J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
    Tamblyn DJ; Chopra S; Yu C; Kattan MW; Pinnock C; Kopsaftis T
    BJU Int; 2011 Nov; 108 Suppl 2():51-6. PubMed ID: 22085129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study.
    Holmström B; Holmberg E; Egevad L; Adolfsson J; Johansson JE; Hugosson J; Stattin P;
    J Urol; 2010 Oct; 184(4):1322-7. PubMed ID: 20723940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radical prostatectomy for clinical T4 prostate cancer.
    Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
    Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
    Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
    J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Dorey FJ; Walsh PC; Partin AW
    J Clin Oncol; 2007 May; 25(13):1765-71. PubMed ID: 17470867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.
    King CR; Freedland SJ; Terris MK; Kane CJ; Amling CL; Aronson WJ; Presti JC
    Urology; 2007 May; 69(5):921-6. PubMed ID: 17482935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer.
    Ramos CG; Roehl KA; Antenor JA; Humphrey PA; Catalona WJ
    J Urol; 2004 Jul; 172(1):137-40. PubMed ID: 15201754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities.
    Tewari A; Johnson CC; Divine G; Crawford ED; Gamito EJ; Demers R; Menon M
    J Urol; 2004 Apr; 171(4):1513-9. PubMed ID: 15017210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.